Purpose of Review

The goal of this review is to summarize current literature on electronic glucose management systems (eGMS) and discuss their benefits and disadvantages in the inpatient setting.

Recent Findings

We review different versions of commercially available eGMS: Glucommander™ (Glytec, Greenville, SC), EndoTool^R (MD Scientific LLC, Charlotte, NC), GlucoStabilizer™ (Medical Decision Network, Charlottesville, VA), GlucoCare™ (Pronia Medical Systems, KY), and discuss advantages such as reducing rates of hypoglycemia, hyperglycemia, and glycemic variability. In addition, eCGMs offer a uniform standard of care and may improve workflows across institutions as well reduce barriers.

Summary

Despite ample literature on intravenous (IV) versions of eGMS, there is little published research on subcutaneous (SQ) insulin guidance. Although use of eGMS requires extensive training and institution-wide adoption, time spent on diabetes management is better facilitated by their use.

中文翻译：

---

静脉和皮下电子血糖管理系统的住院血糖控制的综述。

审查目的

这篇综述的目的是总结有关电子葡萄糖管理系统（eGMS）的最新文献，并讨论它们在住院环境中的利弊。

最近的发现

我们审查了各种不同版本的市售eGMS：Glucommander™（Glytec，格林维尔，SC），EndoTool ^R（MD Scientific LLC，夏洛特，北卡罗来纳州），GlucoStabilizer™（医疗决策网络，夏洛茨维尔，弗吉尼亚州），GlucoCare™（Pronia Medical Systems KY），并讨论诸如降低低血糖症，高血糖症和血糖变异性的优势。另外，eCGM提供统一的护理标准，并可以改善跨机构的工作流程并减少障碍。

概要

尽管有关eGMS静脉（IV）版本的文献很多，但关于皮下（SQ）胰岛素指导的研究很少。尽管使用eGMS需要接受广泛的培训并在机构范围内采用，但使用eGMS可以更好地促进花费在糖尿病管理上的时间。